Grand Pharmaceutical Group Limited (HKG:0512)
8.16
-0.05 (-0.61%)
At close: Dec 5, 2025
Revenue by Product
Fiscal year is January - December.
Year Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
|---|---|---|---|---|---|---|
| Pharmaceutical Technology Products | 7.32B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Technology Products Growth | 7.41% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Bio-technology Products | 3.51B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Bio-technology Products Growth | 3.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Nuclear Medicine Anti-tumor Diagnosis and Treatment and Cerebro-cardiovascular Precision Interventional Diagnosis and Treatment Technology Products | 816.21M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Nuclear Medicine Anti-tumor Diagnosis and Treatment and Cerebro-cardiovascular Precision Interventional Diagnosis and Treatment Technology Products Growth | 143.36% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Year Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
|---|---|---|---|---|---|---|
| China | 10.05B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Growth | 15.18% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| America | 589.43M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| America Growth | -14.26% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe | 478.29M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Growth | -14.93% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia | 474.96M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia Growth | -7.25% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 55.98M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 22.03% |
Log In |
Log In |
Log In |
Log In | Upgrade
|